Dr. Noah Lechtzin, MD

Dr. Lechtzin practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Lechtzin's NPI, 1932147964, was assigned on June 3, 2006. Dr. Lechtzin graduated from Temple University School of Medicine in 1994. Dr. Lechtzin holds Maryland license D51965.

Dr. Lechtzin's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Lechtzin's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Lechtzin is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Lechtzin to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lechtzin practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Lechtzin's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Lechtzin is licensed in Maryland.

CMS data shows 135 Medicare services from Dr. Lechtzin across 3 procedure codes in 2024, for 92 Medicare patients. Medicare paid $19,221 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 92 Medicare patients who saw Dr. Lechtzin in 2024. The largest group is 65 to 74, with 34 patients. 74% of them have high blood pressure, and 68% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lechtzin's median patient age at 58, with 49% women.

In 2024, Dr. Lechtzin wrote 242 Medicare Part D claims for 47 patients. 54% of them were for generic drugs. CMS names the drug for 102 of them, across 5 drugs with 11 or more claims each, at $1,722,678 in total drug cost. In 2023, CMS named 113 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Lechtzin for performance year 2024, reported as part of a group. CMS lists Dr. Lechtzin as offering telehealth.

Dmand AI links 51 papers to Dr. Lechtzin, published from 2016 to 2025. 2018 was the busiest year, with 7. The most frequent topics are Cystic Fibrosis, Amyotrophic Lateral Sclerosis and Anti-Bacterial Agents. Dr. Lechtzin has published most often in J Cyst Fibros. Dr. Lechtzin's most frequent co-authors are Jinsy Andrews, MD, Mark Thomas Jennings, MD and Carlayne E. Jackson, MD.

CMS Open Payments shows 72 general payments to Dr. Lechtzin from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Vertex Pharmaceuticals Incorporated paid the most, $27,226. It also lists 1 research payment totaling $1,500 in 2016.

Dr. Lechtzin graduated from Temple University School of Medicine in 1994.